<?xml version="1.0" encoding="UTF-8" ?>
<modsCollection xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" xmlns:slims="http://slims.web.id" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
<mods version="3.3" id="2138">
 <titleInfo>
  <title>COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE AND CEFIXIME IN TYPHOID FEVER PATIENTS HOSPITALIZED AT BERKAH PANDEGLANG REGIONAL HOSPITAL FOR THE PERIOD 2020-2021</title>
 </titleInfo>
 <name type="Personal Name" authority="">
  <namePart>YUSRANSYAH dkk</namePart>
  <role>
   <roleTerm type="text">Primary Author</roleTerm>
  </role>
 </name>
 <typeOfResource manuscript="no" collection="yes">mixed material</typeOfResource>
 <genre authority="marcgt">bibliography</genre>
 <originInfo>
  <place>
   <placeTerm type="text"></placeTerm>
   <publisher>JURNAL FARMASI SAINS DAN PRAKTIK</publisher>
   <dateIssued>2023</dateIssued>
  </place>
 </originInfo>
 <language>
  <languageTerm type="code">en</languageTerm>
  <languageTerm type="text">English</languageTerm>
 </language>
 <physicalDescription>
  <form authority="gmd">Text</form>
  <extent></extent>
 </physicalDescription>
 <note>ABSTRACT&#13;
Typhoid fever is an infectious disease among humans caused by the bacterium &#13;
Salmonella typhi. With the high Multi-Drug Resistance (MDR) of Salmonella &#13;
typhi, selecting the right antibiotic is a factor that must be considered in addition &#13;
to cost constraints. Therefore, cost-effectiveness is needed. This study aims to &#13;
determine the cost-effectiveness of typhoid fever patients using ceftriaxone and &#13;
cefixime antibiotics. The data used are retrospective, and the sampling was done &#13;
by purposive sampling. This study was conducted at Berkah Pandeglang &#13;
Regional Hospital. Sample in this study, namely typhoid fever patients of the &#13;
period 2020-2021, who meet the inclusion and exclusion criteria. In this study, &#13;
16 samples were obtained. The results of this study showed that the total average &#13;
direct medical costs for the ceftriaxone group were IDR 78.632.500 In contrast, &#13;
the cefixime group was IDR 75.527.300. The ACER value of typhoid fever &#13;
patients who used Ceftriaxone + cefixime was IDR 91,646.27, Ceftriaxone was &#13;
IDR 77,463.89, and cefixime was IDR 88,027.15. The patients with typhoid fever &#13;
who used Ceftriaxone were more cost-effective than those who used Cefixime.&#13;
Keywords: Typhoid Fever; Ceftriaxone; Cefixime; Cost-Effectiveness Analysis&#13;
</note>
 <note type="statement of responsibility"></note>
 <subject authority="">
  <topic>FARMASI</topic>
 </subject>
 <classification>P043</classification>
 <identifier type="isbn"></identifier>
 <location>
  <physicalLocation>PERPUSTAKAAN SALSABILA Sistem Informasi Perpustakaan STIKes Salsabila Serang</physicalLocation>
  <shelfLocator>P043</shelfLocator>
  <holdingSimple>
   <copyInformation>
    <numerationAndChronology type="1">P043</numerationAndChronology>
    <sublocation>RAK UMUM</sublocation>
    <shelfLocator>P043</shelfLocator>
   </copyInformation>
  </holdingSimple>
 </location>
 <slims:digitals>
  <slims:digital_item id="164" url="" path="/fc4b0682939acccd9393c1f2d7cf8b19.pdf" mimetype="application/pdf">COST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE AND  CEFIXIME IN TYPHOID FEVER PATIENTS HOSPITALIZED AT  BERKAH PANDEGLANG REGIONAL HOSPITAL FOR THE  PERIOD 2020-2021</slims:digital_item>
 </slims:digitals>
 <recordInfo>
  <recordIdentifier>2138</recordIdentifier>
  <recordCreationDate encoding="w3cdtf">2023-08-07 09:36:33</recordCreationDate>
  <recordChangeDate encoding="w3cdtf">2023-08-07 09:36:33</recordChangeDate>
  <recordOrigin>machine generated</recordOrigin>
 </recordInfo>
</mods>
</modsCollection>